P/E ratio for Halozyme Therapeutics (HALO)

P/E ratio history for Halozyme Therapeutics from 2004 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
MannKind Corp MNKD	-36.5	-229.65%	🇺🇸 USA
Eli Lilly LLY	138	389.80%	🇺🇸 USA
Baxter BAX	6.52	-76.82%	🇺🇸 USA
Pfizer PFE	13.7	-51.22%	🇺🇸 USA
Sanofi SNY	15.2	-45.90%	🇫🇷 France
Johnson & Johnson JNJ	11.0	-60.98%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.